Novasenta
Pittsburgh, US · Founded 2018 · Delaware corporation
Novasenta is a biotechnology company that uses single-cell analysis of human tissue samples combined with computational biology to discover novel therapeutic targets and develop treatments for immune-mediated diseases and cancer.
Founders & leadership
Novasenta was founded in 2018 by Greg Delgoffe, Greg M. Delgoffe, Robert Ferris, and Dario A. A. Vignali.
GD
Greg DelgoffeCo-founder
GM
Greg M. DelgoffeCo-Founder & Director
RF
Robert FerrisCo-Founder & Scientific Advisor
DA
Dario A. A. VignaliCo-Founder
MK
Matthias KleinzNamed on SEC filing
MM
Mani MohindruNamed on SEC filing
Board
JC
Jeanne CunicelliBoard director
Reported raises · per SEC filings
Form D private placements$25M disclosed across 2 rounds · 2022–2023
▶$15MraisedFeb 2024 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David MooreDirector
- Greg DelgoffeDirector
- Jeanne CunicelliDirector
- Mani MohindruExecutive Officer, Director
- Matthias KleinzDirector
- Offering amount
- $30M
- Amount sold
- $15M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJul 2022 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedJul 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthias KleinzDirector
- Mani MohindruExecutive Officer, Director
- Jeanne CunicelliDirector
- Greg DelgoffeDirector
- Offering amount
- $20M
- Amount sold
- $10M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapGenenta7 shared keywordsGenenta Science is a clinical-stage biotechnology company developing Temferon, a hematopoietic stem cell-based gene therapy platform for treating cancer. The company is publicly traded on Nasdaq under the ticker GNTA.
Zentalis7 shared keywordsZentalis is a clinical-stage pharmaceutical company developing azenosertib, an investigational oral therapy that inhibits WEE1 kinase to disrupt the cell-cycle safeguards cancer cells use to survive. It focuses on providing physicians and patients with a targeted, non-chemotherapy oral treatment option in oncology.
UPMC7 shared keywordsUPMC operates a network of hospitals and health care facilities, offering medical services and specialties such as cancer care, cardiology, neurosciences, orthopaedics, and behavioral health. It provides patient tools for finding doctors, locating facilities by region, and accessing patient portals.
Enanta Pharmaceuticals6 shared keywordsEnanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need. Its work has contributed to hepatitis C virus combination therapies, and its pipeline includes programs in areas such as respiratory syncytial virus (RSV).
Companies competing with Novasenta for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Novasenta do?
- Novasenta is a biotechnology company that uses single-cell analysis of human tissue samples combined with computational biology to discover novel therapeutic targets and develop treatments for immune-mediated diseases and cancer.
- Who founded Novasenta?
- Novasenta was founded by Greg Delgoffe, Greg M. Delgoffe, Robert Ferris, Dario A. A. Vignali in 2018.
- How much funding has Novasenta raised?
- Novasenta has disclosed $25M raised across 2 rounds.
- Where is Novasenta headquartered?
- Novasenta is headquartered in Pittsburgh, US.